Regenlab USA Inc.

What the company does

RegenLab USA develops and commercializes medical devices and other product candidates whose market success depends on regulatory approvals and reimbursement from third-party payors. The company faces competition from existing and emerging technologies and depends on healthcare professionals, commercial partners, distributors, and its internal sales force to commercialize its products.

Use of proceeds

The company intends to use the net proceeds from the offering for sales and marketing, machine equipment for factories in France, Switzerland, and the United States, and research and development and regulatory expenses for clinical studies in Europe and the United States.

Underwriters

Extracted from S-1/A 0001829126-26-011539, filed Oct 27, 2026 and verified against that filing text.

Key risk factors

• Regulatory approval risk

  “The success of our business model depends on obtaining and maintaining regulatory approvals and clearances to market our products.”

• Additional trial requirements

  “Even if we complete clinical testing and receive approval for a medical device, the FDA or other comparable regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials or for a more limited indication or patient population than we originally requested.”

• Reimbursement risk

  “The successful continued commercialization of our products and any other product candidates will depend on obtaining reimbursement of our medical devices from third party payors.”

• Technology and competition risk

  “Our business and product sales may be impacted by alternative technologies and the emergence of new technologies.”

• Historical losses and debt

  “We have a history of operating losses, negative cash flows from operations, and substantial indebtedness, and we may be unable to generate sufficient cash flow to meet our debt obligations or fund our operations.”

• Additional capital needs

  “The net proceeds from this offering, together with our existing cash resources, may not be sufficient to fund our operations, service our debt, or maintain profitability, and we may need to raise additional capital in the future, which may not be available on acceptable terms, or at all.”

• Controlled company risk

  “Despite the fact we do not intend to take advantage of these exemptions, our status as a controlled company could make our common stock less attractive to some investors or otherwise harm our stock price.”

• Immediate dilution

  “You will incur immediate and substantial dilution as a result of this offering.”